Skip to main content
Journal cover image

RNA-targeted therapeutics in cardiovascular disease: the time is now.

Publication ,  Journal Article
Krychtiuk, KA; Rader, DJ; Granger, CB
Published in: European heart journal. Cardiovascular pharmacotherapy
December 2022

Ribonucleic acid (RNA)-targeted therapeutics, including antisense oligonucleotide technologies as well as small interfering RNAs (siRNAs), represent a new class of medications that may overcome several of the disadvantages of small molecule drugs or monoclonal antibodies. Specifically, upstream targeting at the messenger RNA (mRNA) level renders any disease-related protein a potential target, even those pathways previously deemed 'undruggable'. Additional advantages include the comparably simple and cost-effective way of manufacturing and the long dosing intervals. A few agents are already approved and a wide array of cardiovascular drugs is in development, aimed at hypercholesterolaemia, hypertension, myocardial storage diseases, and the coagulation system. Here, we provide an update on the current status of RNA-targeted therapeutics in the cardiovascular arena.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

European heart journal. Cardiovascular pharmacotherapy

DOI

EISSN

2055-6845

ISSN

2055-6837

Publication Date

December 2022

Volume

9

Issue

1

Start / End Page

94 / 99

Related Subject Headings

  • RNA, Small Interfering
  • Oligonucleotides, Antisense
  • Oligonucleotides
  • Hypercholesterolemia
  • Humans
  • Cardiovascular Diseases
  • 3214 Pharmacology and pharmaceutical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Krychtiuk, K. A., Rader, D. J., & Granger, C. B. (2022). RNA-targeted therapeutics in cardiovascular disease: the time is now. European Heart Journal. Cardiovascular Pharmacotherapy, 9(1), 94–99. https://doi.org/10.1093/ehjcvp/pvac052
Krychtiuk, Konstantin A., Daniel J. Rader, and Christopher B. Granger. “RNA-targeted therapeutics in cardiovascular disease: the time is now.European Heart Journal. Cardiovascular Pharmacotherapy 9, no. 1 (December 2022): 94–99. https://doi.org/10.1093/ehjcvp/pvac052.
Krychtiuk KA, Rader DJ, Granger CB. RNA-targeted therapeutics in cardiovascular disease: the time is now. European heart journal Cardiovascular pharmacotherapy. 2022 Dec;9(1):94–9.
Krychtiuk, Konstantin A., et al. “RNA-targeted therapeutics in cardiovascular disease: the time is now.European Heart Journal. Cardiovascular Pharmacotherapy, vol. 9, no. 1, Dec. 2022, pp. 94–99. Epmc, doi:10.1093/ehjcvp/pvac052.
Krychtiuk KA, Rader DJ, Granger CB. RNA-targeted therapeutics in cardiovascular disease: the time is now. European heart journal Cardiovascular pharmacotherapy. 2022 Dec;9(1):94–99.
Journal cover image

Published In

European heart journal. Cardiovascular pharmacotherapy

DOI

EISSN

2055-6845

ISSN

2055-6837

Publication Date

December 2022

Volume

9

Issue

1

Start / End Page

94 / 99

Related Subject Headings

  • RNA, Small Interfering
  • Oligonucleotides, Antisense
  • Oligonucleotides
  • Hypercholesterolemia
  • Humans
  • Cardiovascular Diseases
  • 3214 Pharmacology and pharmaceutical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology